ALMS - Alumis Inc.
Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 – On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3.
Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Risk and Volatility Tango Therapeutics has a beta of
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Valuation and Earnings This table compares Pyxis Oncology
Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk. Profitability This table compares Alumis and Alvotech's net margins,
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the company's stock, valued at approximately $6,377,000. Bank of New York Mellon Corp owned about 0.18% of Alumis at
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The recent share price crash, driven by a lupus trial failure, is significant but may not erase envudeucitinib's potential.
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a mid-stage trial.
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate envudeucitinib's potential in interferon-driven immune-mediated diseases – – Envudeucitinib was generally well tolerated with no new safety signals observed – – Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 – – Conference call and webcast scheduled for September 1 at 8:30 am EDT – SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population.
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,845 shares of the company's stock after purchasing an additional 77,364 shares during the period. California
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin clearance rates for patients with immune-mediated diseases.
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline of 86% from the average daily volume of 2,138,687 shares. The stock had previously closed at $27.23. Wall Street Analysts
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.